Myeloid Differentiation Factor 88 (MYD88) Gene Mutation in Diffuse Large B-Cell Lymphomas: Should it be Included in Routine?

被引：0
|
作者：
Fogliatto, Laura [1 ,2 ,4 ]
Barra, Marines [3 ]
Strey, Yuri [4 ]
Oliveira, Paula [4 ]
Bendit, Israel [5 ]
Bender, Camila [1 ,2 ]
Grokoski, Kamila [1 ,2 ]
Costa, Tito [1 ,2 ]
Kramer, Andrea [4 ]
Bica, Claudia [4 ]
机构：
[1] Hosp Clin Porto Alegre, Serv Hematol & Transplante Medula Ossea, Porto Alegre, RS, Brazil
[2] Hosp Clin Porto Alegre, Grp Pesquisa Clin Hematol, Porto Alegre, RS, Brazil
[3] Irmandade Santa Casa Misericordia Porto Alegre, Dept Patol, Porto Alegre, RS, Brazil
[4] Univ Fed Ciencias Saude Porto Alegre, Programa Posgrad Patol, Porto Alegre, RS, Brazil
[5] Univ Fed Sao Paulo, Lab Biol Tumoral, Sao Paulo, SP, Brazil
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷
关键词：
D O I：
10.1016/j.clml.2017.07.216
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
NHL-193
引用
收藏
页码：S375 / S375
页数：1
相关论文
共 50 条
  • [1] High Prevalence of MYD88 Mutation in Testicular Diffuse Large B-Cell Lymphoma
    Oishi, Naoki
    Kondo, Tetsuo
    Nakazawa, Tadao
    Mochizuki, Kunio
    Tanioka, Fumihiko
    Oyama, Toshio
    Yamamoto, Tomoko
    Iizuka, Junpei
    Tanabe, Kazunari
    Shibata, Noriyuki
    Kirito, Keita
    Katoh, Ryohei
    MODERN PATHOLOGY, 2015, 28 : 369A - 369A
  • [2] High Prevalence of MYD88 Mutation in Testicular Diffuse Large B-Cell Lymphoma
    Oishi, Naoki
    Kondo, Tetsuo
    Nakazawa, Tadao
    Mochizuki, Kunio
    Tanioka, Fumihiko
    Oyama, Toshio
    Yamamoto, Tomoko
    Iizuka, Junpei
    Tanabe, Kazunari
    Shibata, Noriyuki
    Kirito, Keita
    Katoh, Ryohei
    LABORATORY INVESTIGATION, 2015, 95 : 369A - 369A
  • [3] Targeting of Diffuse Large B-cell Lymphomas using MyD88 small molecule inhibitors
    Snyder, Greg A.
    Brown, Lindsey J.
    Taylor, Savannah
    Faupel, Ciara E.
    Sherman, Matthew
    Montague, Justin J.
    Saikh, Kamal
    Wang, Yajing
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [4] In vivo modeling of diffuse large B cell lymphoma (DLBCL) with the myeloid differentiation primary response gene 88 (MYD88) L265P mutation
    Ngo, Vu N.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S852 - S854
  • [5] Select Targeting of Diffuse Large B-cell Lymphomas using MyD88 small molecule inhibitors
    Wang, Yajing
    Brown, Lindsay
    Faupel, Ciara
    Sherman, Matthew
    Montague, Justin
    Beadenkopf, Robert
    Saikh, Kamal
    Snyder, Greg
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 81 : 62 - 62
  • [6] UTILITY OF MYD88 MUTATION TESTING IN SMALL B CELL LYMPHOMAS WITH PLASMACYTIC DIFFERENTIATION
    Wang, Xiaohua
    Fan, Guang
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2018, 40 : 156 - 156
  • [7] Myeloid differentiation primary response gene 88 (MyD88) deficiency in a large kindred
    Conway, Daniel H.
    Dara, Jasmeen
    Bagashev, Asen
    Sullivan, Kathleen E.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 126 (01) : 172 - 175
  • [8] DOES THE MUTATION IN THE MYD88 L265P GENE IN DIFFUSE LARGE B-CELL LYMPHOMAS HAVE INDEPENDENT DIAGNOSTIC SIGNIFICANCE?
    Kovrigina, A. M.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2024, 69 (04):
  • [9] MYD88 expression and L265P mutation in diffuse large B-cell lymphoma
    Choi, Jung-Woo
    Kim, Younghye
    Lee, Ju-Han
    Kim, Young-Sik
    HUMAN PATHOLOGY, 2013, 44 (07) : 1375 - 1381
  • [10] MYD88 (L265P) MUTATION IS AN INDEPENDENT PROGNOSTIC FACTOR IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
    Fernandez, C.
    Garcia, M.
    Sanchez, B.
    Vela, M. C.
    Pairet, S.
    Camacho, L.
    Gimeno, E.
    Senin, A.
    Besses, C.
    Serrano, S.
    Salar, A.
    Bellosillo, B.
    HAEMATOLOGICA, 2014, 99 : 149 - 149
12345